PZ-CLM-SCORECARD-2024: PEPFAR Zambia CLM Scorecard 2024
Closed
This grant is closed. A newer notice from the same program is open now: Advancing Global Health (DFOP0017890). Status: Closes February 14, 2027 (99 days left). It is in our archive of U.S. Mission to Zambia notices from 2023.
U.S. Mission to Zambia offered grants of up to $50,000 (at least $20,000) to nonprofits. It expected to make one award worth $50,000 in total. Applications closed on June 30, 2023.
From the official notice on Grants.gov, last changed May 2, 2023. Checked November 7, 2026.
- Award ceiling$50,000
- Award floor$20,000
- Total funding$50,000
- Expected awards1
- Cost sharingNot required
- Funding typeCooperative Agreement
Key dates
| Posted | May 2, 2023 |
|---|---|
| Deadline | June 30, 2023 |
Who can apply
This opportunity was open to nonprofits.
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
1. Not-for-profit key population-led civil society organizations. A key population-led organization is an organization in which the majority of leadership and/or decision-making staff identify as members or former members of key population communities in which they serve.2. Organizations registered with the Government of the Republic of Zambia 3. Must have experience of successfully implementing similar programs with funding of a minimum of $15,000.4. Must have established offices at least 12 months prior to application submission. Organization must provide a support letter from the National Key Population Technical Working Group.
Is this a realistic fit?
- Past The U.S. President's Emergency Plan for AIDS Relief Programs awards averaged $146,897; this notice allows up to $50,000 per award.
- Most of the program's money (74% over five years) went to nonprofits.
- No cost sharing or match is required.
What the grant funds
For Details please see full NOFO in Related Documents Section 1: PROGRAM DESCRIPTION AND OBJECTIVES Program Description The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) Zambia in collaboration with the Government of the Republic of Zambia’s Ministry of Health (MOH) and the National HIV/AIDS/STI/TB Council (NAC) requests applications for an open competition from key population-led organizations to develop and implement a scorecard as part of PEPFAR Zambia’s efforts to strengthen community-led monitoring (CLM). The scorecard will assess the quality of and barriers to HIV prevention and treatment for key populations in Lusaka and Livingstone districts. PEPFAR defines a key population-led organization as an organization in which the majority of leadership and/or decision-making staff identify as members or former members of key population. PEPFAR recognizes the necessity of key population involvement in the collection and use of data to improve health outcomes and strengthen technical capacity. This funding opportunity seeks to improve the uptake and quality of HIV services for key population communities in Zambia. This will be done in a systematic approach by soliciting, collecting, and analyzing feedback from key population recipients of care to identify gaps in HIV service provision. In addition, the MOH supported sites will be engaged to provide information on key population accessed HIV services. The proposed scorecard is a participatory monitoring tool aimed at engaging key populations to assess the availability and quality of HIV prevention and treatment services and track the implementation of actionable recommendations to facilitate improvements. The tool is participatory in nature as it brings together the service providers (MOH) and users (key populations) in a respectful way to jointly monitor and evaluate services provided at the health facilities and address identified barriers. The scorecard will be a CLM tool designed by and implemented by a key population-led organization. Subject to availability of funding, implementation of the scorecard will be phased beginning with a pilot in Lusaka and Livingstone districts. The lessons learned will inform a potential expansion to other districts using a harmonized approach from the pilot phase.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before
From fiscal 2021 to 2025, The U.S. President's Emergency Plan for AIDS Relief Programs (19.029) awarded $117 million across 794 grant awards, an average of $146,897 per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. | Maryland | 1 | $89.9 million |
| Miscellaneous Foreign Awardees | 321 | $7.9 million | |
| Ho Chi Minh City HIV/AIDS Association | 4 | $673,404 | |
| Tamra for Social Development Organization (TDS) | 3 | $638,998 | |
| National Empowerment Network of People Living with HIV / AIDS (Nephak) | 3 | $513,403 |
Applying now
This notice no longer takes applications. Apply under the newer notice, DFOP0017890, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PZ-CLM-SCORECARD-2024 still open?
No. It closed on June 30, 2023. A newer notice is open: DFOP0017890, closes February 14, 2027 (99 days left).
Who can apply for PEPFAR Zambia CLM Scorecard 2024?
U.S. Mission to Zambia accepted applications from nonprofits. The notice adds further conditions, so read its eligibility section.
What is the deadline for PEPFAR Zambia CLM Scorecard 2024?
Closed June 30, 2023. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $50,000 each. About $50,000 in total for one award.
Who has won The U.S. President's Emergency Plan for AIDS Relief Programs grants before?
The largest recipients over five fiscal years were The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Miscellaneous Foreign Awardees, Ho Chi Minh City HIV/AIDS Association. The program made 794 awards worth $117 million in that time.
Similar open grants
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)
- Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required)
- Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required)